Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015

Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015

UNION CITY, Calif., Oct. 21, 2014 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today reported financial results for the second fiscal quarter ended September 30, 2014.

Second quarter overview:

  • Revenues of $53.9 million, up 18% over last year's comparable quarter.
  • Diluted EPS of $0.24, up 33% over last year's comparable quarter.

Revenues highlights:

  • Service revenues from Abaxis Veterinary Reference Laboratories (AVRL) of $3.5 million, up 50% over last year's comparable quarter.
  • Total medical and veterinary reagent disc revenues of $28.0 million, up 33% over last year's comparable quarter.
  • Total consumables revenues of $38.1 million, up 33% over last year's comparable quarter.
  • Total medical and veterinary reagent disc sales of 2.1 million units, up 30% over last year's comparable quarter.
  • Veterinary market revenues of $45.6 million, up 20% over last year's comparable quarter.
  • North America revenues of $44.5 million, up 19% over last year's comparable quarter.
  • International revenues of $9.4 million, up 11% over last year's comparable quarter.
  • Medical market revenues of $7.6 million, up 6% over last year's comparable quarter.

Other financial highlights:

  • Gross profit of $28.4 million, up 30% over last year's comparable quarter.
  • Income from operations of $8.9 million, up 57% over last year's comparable quarter.
  • Cash, cash equivalents and investments as of September 30, 2014 of $126.3 million, an increase of $5.1 million from March 31, 2014.
  • Cash dividend of $0.10 per share paid during the second quarter of fiscal 2015.

Quarterly Results

For the fiscal quarter ended September 30, 2014, Abaxis reported revenues of $53.9 million, as compared with revenues of $45.9 million for the comparable period last year, an increase of 18 percent.  Revenues from sales of instruments, which include chemistry analyzers, hematology instruments, VSpro specialty analyzers and i-STAT analyzers, decreased by $3.4 million, or 25 percent, compared to the same period last year.  Revenues from sales of consumables, which include reagent discs, hematology reagent kits, VSpro specialty cartridges, i-STAT cartridges and rapid tests, increased by $9.4 million, or 33 percent, compared to the same period last year.  Abaxis reported net income of $5.4 million for the fiscal quarter ended September 30, 2014, compared to $4.0 million for the fiscal quarter ended September 30, 2013.  Abaxis' effective tax rate in the quarter ended September 30, 2014 was 36 percent, unchanged from the same period last year.  Abaxis reported diluted net income per share of $0.24 (calculated based on 22,690,000 shares) for the three-month period ended September 30, 2014, compared to $0.18 per share (calculated based on 22,574,000 shares) for the same period last year. 

Six-Month Results

For the six-month period ended September 30, 2014, Abaxis reported revenues of $101.4 million, as compared with revenues of $89.0 million for the comparable period last year, an increase of 14 percent.  Revenues from instrument sales decreased by $4.5 million, or 20 percent, compared to the same period last year.  Revenues from consumables increased by $13.1 million, or 22 percent, over the same period last year.  The company reported net income of $10.1 million for the six-month period ended September 30, 2014, compared to $7.2 million for the same period last year.  The company's effective tax rate in the six-month period ended September 30, 2014 was 37 percent, compared to 36 percent for the same period last year.  The company reported diluted net income per share of $0.45 (calculated based on 22,678,000 shares) for the six-month period ended September 30, 2014, compared to $0.32 per share (calculated based on 22,589,000 shares) for the same period last year.

Other Reported Information

Total sales in the medical market for the second quarter of fiscal 2015 were $7.6 million, an increase of 6 percent, compared to the same period last year.  Total sales in the veterinary market for the second quarter of fiscal 2015 were $45.6 million, an increase of 20 percent, compared to the same period last year.  Total medical and veterinary reagent disc sales for the second quarter of fiscal 2015 were $28.0 million, an increase of 33 percent, compared to the same period last year.  Total unit sales of medical and veterinary reagent discs for the second quarter of fiscal 2015 were 2.1 million units, an increase of 30 percent, compared to the same period last year.  Total medical and veterinary instrument sales for the second quarter of fiscal 2015 were $10.1 million, a decrease of 25 percent, compared to the same period last year.  Total unit sales of medical and veterinary instruments for the second quarter of fiscal 2015 were 1,436 units, a decrease of 19 percent, compared to the same period last year.  Non-cash compensation expense recognized for share-based awards during the second quarter of fiscal 2015 was $2.5 million, compared to $1.9 million for the same period last year.  Abaxis paid $2.3 million in cash dividends to shareholders during the second quarter of fiscal 2015. 

Clint Severson, chairman, president and chief executive officer of Abaxis, said, "The financial results of the second quarter of fiscal 2015 were strong and demonstrate that the positive momentum generated in the first quarter of the year is continuing.  We posted revenues of $53.9 million for the second quarter, our highest quarterly revenues ever and an increase of 18% compared to last year's comparable quarter.  Gross margin was 53% for the quarter, an increase of 5%, compared to 48% in last year's second quarter.  In our veterinary business we sold a record quarterly total of VetScan VS2s, 831 units, up 44% compared to the second quarter of fiscal 2014, along with veterinary reagent disc sales of 1.4 million units, which increased by 39% compared to last year's comparable quarter.  In the medical market, unit sales of Piccolo instruments decreased by 13% from last year's comparable quarter, mostly due to the timing of distributor orders; however, medical reagent disc unit sales increased by14%.  Total veterinary and medical reagent disc sales for the second quarter of fiscal 2015 were a record 2.1 million units.  Our recent product supply and co-marketing relationship with VCA Inc. continues to progress well and we look forward to continue providing our VetScan diagnostic solutions to VCA's animal hospitals located in North America.  We are excited with the significant opportunities ahead." 

Mr. Severson continued, "All in all, we are very pleased with the progress achieved in the first half of fiscal 2015.  This is a direct result of executing on our strategic initiatives to drive improved operational performance, along with providing our customers with leading edge point-of-care diagnostic testing and full service veterinary reference laboratory services.  Our distribution partners are increasingly becoming more efficient as evidenced by the strong results of the first six months of the fiscal year.  The financial condition of the company continues to be strong as we maintain cash, cash equivalents and investments totaling $126.3 million at September 30, 2014.  We are pleased with the operational and financial performance achieved companywide thus far in fiscal 2015. Looking forward, we will continue to build on this positive momentum and leverage our strategic partnerships to drive growth in the coming quarters."

Conference Call

Abaxis has scheduled a conference call to discuss its financial results at 4:15 p.m. Eastern Time on Tuesday, October 21, 2014.  Participants can dial (877) 317-6789 or (412) 317-6789 to access the conference call, or can listen via a live Internet webcast, which is available in the Investor Relations section of the company's website at http://www.abaxis.com.  A replay of the call will be available by visiting http://www.abaxis.com for the next 30 days or by calling (877) 344-7529 or (412) 317-0088, confirmation code 10054322, through October 28, 2014.  This press release is also available prior to and after the call via Abaxis' website or the Securities and Exchange Commission's website at http://www.sec.gov

About Abaxis

Abaxis develops, manufactures, markets and sells portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements.  The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients.  The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples.  The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.  The veterinary business also provides to the animal health and research market a line of hematology instruments for point-of-care complete blood counts (CBC), a specialty instrument to screen for and detect clotting disorders and to measure equine fibrinogen levels, a handheld instrument for the rapid assessment of certain critical care tests and rapid point-of-care tests for Heartworm infections, Parvovirus, Giardia, Ehrlichia and Lyme disease.  Abaxis, through its AVRL division, provides routine laboratory testing as well as specialty testing for veterinarians nationwide.  For more information, visit http://www.abaxis.com.

Use of Financial Measures

To supplement the financial statements presented in accordance with United States generally accepted accounting principles (GAAP), Abaxis uses operating income per share, a non-GAAP financial measure.  The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.  For more information on this non-GAAP financial measure, refer to the table captioned "Operating Income Per Share" included at the end of this release.  Abaxis defines operating income per share as operating income divided by the weighted average outstanding shares.  Management uses this measure in comparing Abaxis' operating results with historical performance and believes it provides meaningful and comparable information to management and investors to assist in their review of Abaxis' performance relative to prior periods and its competitors.

Forward Looking Statements

This press release includes, and our conference call will include, statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Abaxis' cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations.  Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act.  These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," "anticipates," or words of similar import, and do not reflect historical facts.  Specific forward-looking statements contained in this press release or in Abaxis' conference call may be affected by risks and uncertainties, including, but not limited to, those related to risks related to the transition of its U.S. medical sales to Abbott, potential excess inventory levels and inventory imbalances at the company's distributors, losses or system failures with respect to Abaxis' facilities or manufacturing operations, fluctuations in quarterly operating results, dependence on sole suppliers, the market acceptance of Abaxis' products and services, the continuing development of its products, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Abaxis' intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy.  Readers should also refer to the section entitled "Risk Factors" in Abaxis' annual report on Form 10-K, recent quarterly reports on Form 10-Q and Abaxis' other periodic reports filed with the United States Securities and Exchange Commission.  Forward-looking statements speak only as of the date the statements were made.  Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.

ABAXIS, INC.
Condensed Consolidated Statements of Income
(In thousands, except per share data)
(Unaudited)

 

Three Months Ended

Six Months Ended

 

September 30,

September 30,

 

2014

2013

2014

2013

Revenues

$            53,943

$            45,851

$           101,420

$            89,020

Cost of revenues

25,511

23,979

49,116

46,256

Gross profit

28,432

21,872

52,304

42,764

Operating expenses:

       

   Research and development 

4,232

3,418

8,179

6,591

   Sales and marketing 

11,476

9,902

21,054

19,930

   General and administrative

3,797

2,853

6,705

5,908

Total operating expenses

19,505

16,173

35,938

32,429

Income from operations

8,927

5,699

16,366

10,335

Interest and other income (expense), net

(445)

507

(398)

911

Income before income tax provision

8,482

6,206

15,968

11,246

Income tax provision

3,082

2,210

5,853

4,021

Net income

$              5,400

$              3,996

$             10,115

$              7,225

         

Net income per share:

       

  Basic net income per share

$                0.24

$                0.18

$                 0.45

$                0.32

  Diluted net income per share

$                0.24

$                0.18

$                 0.45

$                0.32

Shares used in the calculation of net income per share:

       

  Weighted average common shares outstanding - basic

22,507

22,306

22,458

22,268

  Weighted average common shares outstanding - diluted

22,690

22,574

22,678

22,589

Cash dividends declared per share

$                0.10

$                      -

$                 0.20

$                      -

 

ABAXIS, INC.
Condensed Consolidated Balance Sheets
(Unaudited and in thousands)

 

September 30, 

March 31,

 

2014

2014

Current assets:

   

 Cash and cash equivalents

$             84,594

$             73,589

 Short-term investments

20,844

29,102

 Receivables, net

36,351

29,227

 Inventories

28,987

26,978

 Prepaid expenses and other current assets

3,954

2,452

 Net deferred tax assets, current

5,990

4,464

   Total current assets 

180,720

165,812

Long-term investments

20,851

18,491

Investment in unconsolidated affiliate

2,614

2,646

Property and equipment, net

28,884

27,176

Intangible assets, net

875

1,624

Net deferred tax assets, non-current

1,555

1,557

Other assets

131

74

   Total assets

$           235,630

$           217,380

     

Current liabilities:

   

 Accounts payable

$             10,143

$               6,111

 Accrued payroll and related expenses

8,802

4,654

 Accrued taxes

764

1,144

 Other accrued liabilities

5,555

3,095

 Deferred revenue

1,226

1,208

 Warranty reserve

1,193

1,047

   Total current liabilities

27,683

17,259

Non-current liabilities:

   

 Deferred rent

768

768

 Deferred revenue

3,576

4,035

 Warranty reserve

992

821

 Notes payable, less current portion

531

581

   Total non-current liabilities

5,867

6,205

   Total liabilities

33,550

23,464

Shareholders' equity:

   

 Common stock

127,163

124,603

 Retained earnings 

74,935

69,318

 Accumulated other comprehensive loss

(18)

(5)

   Total shareholders' equity

202,080

193,916

   Total liabilities and shareholders' equity

$           235,630

$           217,380

The following table presents our calculation of operating income per share for the three and six months ended September 30, 2014 and 2013.

Operating Income Per Share
(In thousands, except per share data)

 

Three Months Ended

Six Months Ended

 

September 30,

September 30,

 

2014

2013

2014

2013

Income from operations

$                8,927

$                5,699

$              16,366

$              10,335

         

Shares used in the calculation of operating income per share:

       

  Weighted average common shares outstanding - basic

22,507

22,306

22,458

22,268

  Weighted average common shares outstanding - diluted

22,690

22,574

22,678

22,589

         

Operating income per share - basic

$                  0.40

$                  0.26

$                  0.73

$                  0.46

Operating income per share - diluted

$                  0.39

$                  0.25

$                  0.72

$                  0.46

The following table presents our revenues by source for the three and six months ended September 30, 2014 and 2013.

Revenues by Geographic Region and Customer Group
(In thousands)

 

Three Months Ended

Six Months Ended

 

September 30,

September 30,

Revenues by Geographic Region

2014

2013

2014

2013

North America

$              44,511

$              37,320

$              82,851

$              71,972

International

9,432

8,531

18,569

17,048

Total revenues

$              53,943

$              45,851

$            101,420

$              89,020

         
 

Three Months Ended

Six Months Ended

 

September 30,

September 30,

Revenues by Customer Group

2014

2013

2014

2013

Medical Market

$                7,616

$                7,177

$              14,861

$              13,215

Veterinary Market

45,568

37,915

84,935

74,286

Other

759

759

1,624

1,519

Total revenues

$              53,943

$              45,851

$            101,420

$              89,020

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/abaxis-reports-record-revenues-for-the-second-quarter-of-fiscal-2015-926993242.html

SOURCE Abaxis, Inc.

Abaxis, Inc., Lytham Partners, LLC, Clint Severson Joe Dorame, Robert Blum and Joe Diaz, Chief Executive Officer 602-889-9700, 510-675-6500

 

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…